Maven Securities LTD Karuna Therapeutics, Inc. Transaction History

Maven Securities LTD

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$123.79 - $277.42 $495,160 - $1.11 Million	4,000 New	4,000 $9 Million
Q1 2022 May 16, 2022	SELL	$98.9 - $132.37 $402,819 - $539,143	-4,073 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$110.64 - $159.4 $450,636 - $649,236	4,073 New	4,073 $534,000
Q3 2021 Nov 15, 2021	SELL	$101.2 - $125.87 $5.06 Million - $6.29 Million	-50,000 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$95.46 - $133.08 $2.39 Million - $3.33 Million	-25,000 Reduced 33.33%	50,000 $5.84 Million
Q4 2020 Feb 12, 2021	BUY	$75.23 - $109.23 $5.64 Million - $8.19 Million	75,000 New	75,000 $7.77 Million
Q1 2020 May 15, 2020	SELL	$60.41 - $115.92 $2.11 Million - $4.06 Million	-35,000 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$11.44 - $123.99 $250,764 - $2.72 Million	21,920 Added 167.58%	35,000 $2.53 Million
Q3 2019 Nov 14, 2019	SELL	$16.05 - $27.35 $191,316 - $326,012	-11,920 Reduced 47.68%	13,080 $213,000
Q2 2019 Aug 13, 2019	BUY	$20.02 - $20.02 $500,500 - $500,500	25,000 New	25,000 $501,000

332K

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

Get notified when there are updates to the investment portfolio of Maven Securities LTD, based on Form 13F filings with the SEC.

Stay updated on Maven Securities LTD with notifications on news.